Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes.

TouchREVIEWS in endocrinology Pub Date : 2022-06-01 Epub Date: 2022-05-20 DOI:10.17925/EE.2022.18.1.27
Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs
{"title":"Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes.","authors":"Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs","doi":"10.17925/EE.2022.18.1.27","DOIUrl":null,"url":null,"abstract":"<p><p>Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"18 1","pages":"27-34"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TouchREVIEWS in endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2022.18.1.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1 型糖尿病自动胰岛素输送系统及相关时间范围结果回顾。
胰岛素自动给药系统(AID)在 1 型糖尿病(T1DM)的治疗中发挥着重要作用。这些系统包括三个组成部分:连续血糖监测仪(CGM)、胰岛素泵和根据 CGM 传感器血糖读数调整泵的算法。这些系统并非完全自动化,仍需要用户为食物注射胰岛素。有些 AID 系统具有自动校正胰岛素剂量的功能,而有些则只有自动调整基础或背景胰岛素的功能。随着 CGM 的精确度提高和技术的发展,AID 系统的血糖治疗效果也得到了改善。在随机对照试验和实际研究中对 AID 系统进行的临床评估表明,它们在帮助进行血糖管理方面非常有用。在这篇综述中,我们比较了美国市售的 AID 系统,并总结了相关文献,特别关注了 T1DM 患者的血糖控制时间。综述还讨论了即将推出的新型 AID 系统,并探讨了个性化护理的注意事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
期刊最新文献
Amyloid Goiter: A Peruvian Case Series. Clinical and Biochemical Profiles of Hospitalized Patients with Hypercalcaemia from a Tertiary Care Centre in North India. Dry Eye in Diabetes: The Indian Diabetic and Endocrine Eye Diseases (INDEED) Review. Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis. Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1